Shots:

• Cerecor to receive up front as $4.5M in cash & $12.5M in Aytu preferred stock- which is approx. 1.4x LTM revenue- plus the assumption of debt
• The transaction will expand Aytu’s annual revenue to $44M and is expected to accelerate time to breakeven- following the acquisition of Innovus Pharmaceuticals
• The purchased commercial portfolio consists of six established- commercialized pediatric primary care products including AcipHex Sprinkle- Cefaclor for Oral Suspension- Karbinal ER- Flexichamber- Poly-Vi-Flor and Tri-Vi-Flor complimenting Aytu’s Natesto- ZolpiMist- and Tuzistra XR

Click here to­ read full press release/ article | Ref: Aytu BioScience | Image: Twitter